This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| NeuroRx Research | |
|---|---|
| Name | NeuroRx Research |
| Type | Research institute |
| Founded | 2014 |
| Founder | Jonathan Javitt |
| Headquarters | Pittsburgh, Pennsylvania, United States |
| Key people | Jonathan Javitt, Michael W. Pourmand |
| Focus | Neuropharmacology; psychiatric therapeutics; psychedelic-assisted therapy |
NeuroRx Research
NeuroRx Research is a clinical-stage biomedical research organization focused on developing novel pharmacotherapies for psychiatric and neurologic disorders. The organization conducts translational research, investigator-initiated trials, and regulatory interactions to advance compounds from preclinical models through Phase 2 and beyond. It engages with academic medical centers, biotechnology firms, and regulatory agencies to position experimental therapeutics for broader clinical use.
NeuroRx Research operates at the intersection of translational neuroscience, clinical psychiatry, and pharmaceutical development, engaging with institutions such as University of Pittsburgh Medical Center, Massachusetts General Hospital, Johns Hopkins Hospital, Mayo Clinic, and Stanford University Medical Center to design and implement trials. The organization’s activities frequently interface with drug developers including Johnson & Johnson, Eli Lilly and Company, Pfizer, Roche, Bristol-Myers Squibb, and smaller biotechnology companies like Atai Life Sciences, MAPS Public Benefit Corporation, and Compass Pathways. Its regulatory strategy involves interaction with agencies such as the Food and Drug Administration and the European Medicines Agency and leverages guidance from professional bodies like the American Psychiatric Association and the World Health Organization.
Founded in 2014, NeuroRx Research grew during a resurgence of interest in novel psychiatric medicines following landmark studies at institutions including Harvard Medical School, Columbia University Irving Medical Center, Yale School of Medicine, University of California, San Francisco, and Imperial College London. Early leadership included clinicians and scientists who previously worked at centers such as Allegheny Health Network and collaborative networks with groups like National Institutes of Health-funded consortia and consortiums linked to the National Institute of Mental Health. The organization’s development tracks parallel advances by researchers associated with figures and labs at David Nutt-linked groups, investigators connected to Roland Griffiths’s work, and teams influenced by Karl Deisseroth’s optogenetics and circuit-mapping methodologies. Expansion was supported through partnerships, grant awards, and industry-sponsored contracts with firms exemplified by Celgene-era investments and venture funding sources tied to Third Rock Ventures.
NeuroRx Research concentrates on pharmacological modulation of mood, anxiety, and trauma-related disorders, drawing on pharmacologists and clinicians trained at University of Pennsylvania Perelman School of Medicine, Northwestern University Feinberg School of Medicine, Duke University School of Medicine, Icahn School of Medicine at Mount Sinai, and Weill Cornell Medicine. Programmatic areas include rapid-acting antidepressants, glutamatergic modulators, monoaminergic agents, and psychedelic-assisted protocols involving compounds studied by groups at Johns Hopkins University School of Medicine, UCLA Health, and New York University Grossman School of Medicine. The organization supports biomarker discovery efforts that collaborate with laboratories tied to Broad Institute, Salk Institute, Cold Spring Harbor Laboratory, and computational platforms developed by groups affiliated with MIT and Carnegie Mellon University.
Clinical trial activities encompass Phase 1–2 studies for treatment-resistant depression, post-traumatic stress disorder, and acute suicidal ideation, conducted at clinical sites including Cleveland Clinic, Northwestern Memorial Hospital, Mount Sinai Beth Israel, and community hospitals affiliated with academic centers. Trials often assess agents related to compounds investigated by companies such as Johnson & Johnson’s ketamine-derivative programs, Janssen Pharmaceuticals initiatives, and programs at Eli Lilly and Allergan for rapid-onset interventions. NeuroRx Research has coordinated adaptive trial designs influenced by statistical methods from investigators at Stanford University and University of Oxford, and has implemented outcome measures consistent with guidance from the American College of Neuropsychopharmacology and multicenter consortia like ENIGMA.
Strategic collaborations include alliances with academic hospitals, biotechnology firms, contract research organizations, and policy groups. Partners have included clinical centers associated with Yale-New Haven Hospital, corporate collaborators such as Sage Therapeutics and Axsome Therapeutics, and research consortia linked to The Michael J. Fox Foundation and Brain & Behavior Research Foundation. The organization also engages with certification and training entities similar to those working with MAPS Public Benefit Corporation for therapist training in psychedelic-assisted therapy and with philanthropic funders like Wellcome Trust and Gates Foundation-supported initiatives in mental health implementation.
NeuroRx Research’s protocols align with oversight frameworks used by institutional review boards at institutions such as Johns Hopkins Hospital and Massachusetts General Hospital, and with regulatory submissions to the Food and Drug Administration and national competent authorities across the European Union. Safety monitoring draws on best practices promulgated by groups including the Clinical Trials Transformation Initiative and standards referenced by the National Institutes of Health. Ethical engagement includes informed consent practices consistent with guidance from Council for International Organizations of Medical Sciences-style documents, attention to risk-benefit frameworks discussed at forums like the World Congress of Psychiatry, and collaboration with bioethics centers at Harvard Medical School and Georgetown University.
Work affiliated with NeuroRx Research has been cited in peer-reviewed journals where authors are connected to institutions like Nature Medicine editorial contributors, investigators associated with The Lancet psychiatry articles, and collaborators publishing in JAMA Psychiatry and Biological Psychiatry. The organization’s programs have been acknowledged at conferences such as the American Psychiatric Association annual meeting, the Society of Biological Psychiatry congress, and the Neuroscience meeting of the Society for Neuroscience. Awards and recognitions for collaborators include honors given by bodies like the Brain Prize, the Nobel Prize-adjacent scientific community, and investigator awards from the National Institutes of Health and private foundations.
Category:Medical research institutes